Promentis Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2006-01-01
- Employees
- 11
- Market Cap
- -
Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- Promentis Pharmaceuticals, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT03887429
- Locations
- 🇺🇸
Celerion Inc., Lincoln, Nebraska, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
A Study in Patients With Trichotillomania
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Promentis Pharmaceuticals, Inc.
- Target Recruit Count
- 128
- Registration Number
- NCT03797521
- Locations
- 🇺🇸
Finger Lakes Clinical Research, Rochester, New York, United States
🇺🇸Integrative Clinical Trials, LLC, Brooklyn, New York, United States
🇺🇸Artemis Institute for Clinical Research, Riverside, California, United States
Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023
- First Posted Date
- 2018-05-31
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Promentis Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03542435
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2019-09-26
- Lead Sponsor
- Promentis Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03301298
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath